Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Conditions
Brief summary
This randomized phase II trial studies how well giving irinotecan hydrochloride with or without alvocidib works in treating patients with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Alvocidib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether irinotecan hydrochloride is more effective with or without alvocidib.
Detailed description
PRIMARY OBJECTIVES: I. To examine the antitumor efficacy of irinotecan (irinotecan hydrochloride) followed by flavopiridol (alvocidib) (Arm A) and of irinotecan alone (Arm B) in patients with advanced gastric/ gastroesophageal junction (GEJ) adenocarcinoma wild type for p53. SECONDARY OBJECTIVES: I. To evaluate the safety and toxicity of both study arms in patients with advanced gastric/GEJ adenocarcinoma. II. To examine other measures of antitumor activity in both study arms, including response rate (in patients with measurable disease) and overall survival. TERTIARY OBJECTIVES: I. To evaluate pre- and post-treatment tumor biopsies for p21 and RAD51 homolog (S. cerevisiae) (Rad51) expression in patients who agree to tumor biopsies (Memorial Sloan-Kettering Cancer Center \[MSKCC\] and Weill-Cornell only). II. To explore the response to irinotecan and flavopiridol and to irinotecan alone by deoxyribonucleic acid (DNA) microarray technology on pre- and post-treatment tumor biopsies (MSKCC and Weill-Cornell only). OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive irinotecan hydrochloride intravenously (IV) over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 1 year.
Interventions
DRUGalvocidib
Given IV
DRUGirinotecan hydrochloride
Given IV
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient must have pathologically confirmed carcinoma of the stomach or GEJ (Siewert's type I, II, or III); confirmation will be performed locally at each participating institution * The patient must have advanced disease not amenable to surgical resection * Patients must have disease that can be evaluated radiographically; this may be measurable disease or non-measurable disease; measurable disease is defined as that which can be measured in at least one dimension as \> 20 mm with conventional techniques, or \> 10 mm by high resolution imaging; disease that is identified on radiology studies, but does not meet the criteria for measurable disease, is considered non-measurable * The patient must have received one prior chemotherapy regimen for his or her unresectable or metastatic disease; this does not include therapy administered in the adjuvant or neoadjuvant setting * At least 2 weeks must have elapsed since the patient received prior chemotherapy, anti-angiogenic therapy, or other targeted therapy; 2 weeks since prior radiation therapy; or, 4 weeks if the last regimen included carmustine (BCNU) or mitomycin C * The patient must have a Karnofsky performance status of \>= 60 * Serum creatinine =\< 2 mg/dl * Total serum bilirubin =\< 2 mg/dl * If the patient has Gilbert's disease and has a serum bilirubin greater than 2.0 mg/dl, the case must be discussed with the principal investigator; such a patient may be considered eligible on a case-by-case basis * Serum aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 times the upper limit of normal, or * Serum AST (SGOT)/ ALT (SGPT) =\< 5 times the upper limit of normal in case of liver metastases * White blood cell (WBC) \>= 3000/mm\^3 * Absolute neutrophil count (ANC) \>= 1000/mm\^3 * Platelets \>= 75,000/mm\^3 * The patient must have available tumor tissue for assessment of p53 status by immunohistochemistry (IHC) (=\< 20% cutoff for positivity) * Tumor must be p53 wild type as defined as =\< %20 nuclear staining on immunohistochemistry * Women of child-bearing potential and sexually active males must be counseled to use an accepted and effective method of contraception (including intrauterine device \[IUD\], oral contraceptives, or barrier devices) while on treatment and for at least two months after their last treatment on this study; woman also must agree to refrain from nursing during the duration of this study and for at least two months after their last treatment on this study; women of child-bearing potential must have a negative serum pregnancy test to be eligible for this study * The patient must have the mental capacity to understand the nature of this study and provide informed consent to participate
Exclusion criteria
* The patient may not have previously received irinotecan or flavopiridol * The patient may not be receiving any other investigational agents * The patient may not have any ongoing grade 2 or greater toxicity from a prior treatment * The patient may not have an ongoing uncontrolled illness including, but not limited to active infection, symptomatic congestive heart failure, myocardial infarction in the past 6 months, or new cardiac arrhythmia in the past 6 months * Patients with a diagnosis of active human immunodeficiency virus (HIV) infection, on anti-retroviral therapy, or with a cluster of differentiation 4 (CD4) count less than 200 are ineligible due to potential interactions between irinotecan, flavopiridol, and anti-retroviral medications as well as possible immunosuppressive activity of the study treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | From the start of treatment for up to 3 months | Response was determined as indicated in the protocol. |
Countries
United States
Participant flow
Recruitment details
Protocol Open to Accrual 09/09/2009 Protocol Closed to Accrual 02/28/2012 Recruitment Location is the medical clinic
Participants by arm
| Arm | Count |
|---|---|
| Irinotecan Hydrochloride and Alvocidib Patients receive irinotecan hydrochloride IV over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Irinotecan: 100 mg/m2 IV over 30 min on days 1 and 8 followed 7 hours later by Flavopiridol 60 mg/m2 IV over 1 hr on days 1 and 8 | 13 |
| Irinotecan Hydrochloride Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Irinotecan: 100 mg/m2 IV over 30 min on days 1 and 8 | 6 |
| Total | 19 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 1 |
Baseline characteristics
| Characteristic | Irinotecan Hydrochloride | Irinotecan Hydrochloride and Alvocidib | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 5 Participants | 7 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 8 Participants | 12 Participants |
| Age, Continuous | 56 years STANDARD_DEVIATION 16.97056275 | 62.5 years STANDARD_DEVIATION 19.091883 | 60 years STANDARD_DEVIATION 22.627417 |
| Region of Enrollment United States | 6 participants | 13 participants | 19 participants |
| Sex: Female, Male Female | 0 Participants | 6 Participants | 6 Participants |
| Sex: Female, Male Male | 6 Participants | 7 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 13 / 13 | 6 / 6 |
| serious Total, serious adverse events | 6 / 13 | 2 / 6 |
Outcome results
Primary
Overall Response Rate
Response was determined as indicated in the protocol.
Time frame: From the start of treatment for up to 3 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Irinotecan Hydrochloride and Alvocidib | Overall Response Rate | Partial Response | 1 participants |
| Irinotecan Hydrochloride and Alvocidib | Overall Response Rate | Stable Disease | 4 participants |
| Irinotecan Hydrochloride and Alvocidib | Overall Response Rate | Progression of Disease | 8 participants |
| Irinotecan Hydrochloride | Overall Response Rate | Partial Response | 0 participants |
| Irinotecan Hydrochloride | Overall Response Rate | Stable Disease | 1 participants |
| Irinotecan Hydrochloride | Overall Response Rate | Progression of Disease | 4 participants |